{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Chaturvedi S"],"funding":["NCATS NIH HHS","NHLBI NIH HHS"],"pagination":["1335-1344"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9710186"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["140(12)"],"pubmed_abstract":["Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is characterized by recurring episodes of thrombotic microangiopathy, causing ischemic organ impairment. Black patients are overrepresented in iTTP cohorts in the United States, but racial disparities in iTTP outcome and response to therapy have not been studied. Using the United States Thrombotic Microangiopathies Consortium iTTP Registry, we evaluated the impact of race on mortality and relapse-free survival (RFS) in confirmed iTTP in the United States from 1995 to 2020. We separately examined the impact of rituximab therapy and presentation with newly diagnosed (de novo) or relapsed iTTP on RFS by race. A total of 645 participants with 1308 iTTP episodes were available for analysis. Acute iTTP mortality did not differ by race. W"],"journal":["Blood"],"pubmed_title":["Race, rituximab, and relapse in TTP."],"pmcid":["PMC9710186"],"funding_grant_id":["K99 HL150594","UL1 TR002494","UL1 TR001111","K08 HL159290"],"pubmed_authors":["Go RS","Upreti HV","Baumann Kreuziger L","Farland AM","McCrae KR","Antun AG","Woods R","Zheng XL","Cataland SR","Davis E","Sadler JE","Johnson A","United States Thrombotic Microangiopathies Consortium","Metjian A","Kasthuri RS","de Ridder G","Mazepa MA","Park YA","Gibson B","Akwaa F","Gangaraju R","Lim MY","Raval JS","Masias C","Clover T","Liu A","Sridharan M","Chaturvedi S","Evans MD","Liles DK"],"additional_accession":[]},"is_claimable":false,"name":"Race, rituximab, and relapse in TTP.","description":"Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is characterized by recurring episodes of thrombotic microangiopathy, causing ischemic organ impairment. Black patients are overrepresented in iTTP cohorts in the United States, but racial disparities in iTTP outcome and response to therapy have not been studied. Using the United States Thrombotic Microangiopathies Consortium iTTP Registry, we evaluated the impact of race on mortality and relapse-free survival (RFS) in confirmed iTTP in the United States from 1995 to 2020. We separately examined the impact of rituximab therapy and presentation with newly diagnosed (de novo) or relapsed iTTP on RFS by race. A total of 645 participants with 1308 iTTP episodes were available for analysis. Acute iTTP mortality did not differ by race. W","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Sep","modification":"2025-04-04T08:24:14.031Z","creation":"2025-04-04T08:24:14.031Z"},"accession":"S-EPMC9710186","cross_references":{"pubmed":["35797471"],"doi":["10.1182/blood.2022016640"]}}